Cubist Systematic Strategies LLC increased its stake in shares of MEDNAX Inc (NYSE:MD) by 1,206.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,891 shares of the company’s stock after buying an additional 10,981 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in MEDNAX were worth $513,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pacer Advisors Inc. grew its holdings in shares of MEDNAX by 8.1% during the second quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock worth $117,000 after buying an additional 145 shares during the last quarter. Commonwealth Bank of Australia grew its holdings in shares of MEDNAX by 15.3% during the second quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after buying an additional 293 shares during the last quarter. Fuller & Thaler Asset Management Inc. purchased a new stake in MEDNAX in the 3rd quarter valued at approximately $103,000. Meiji Yasuda Asset Management Co Ltd. purchased a new stake in MEDNAX in the 2nd quarter valued at approximately $217,000. Finally, QS Investors LLC boosted its holdings in MEDNAX by 0.3% in the 2nd quarter. QS Investors LLC now owns 3,812 shares of the company’s stock valued at $230,000 after purchasing an additional 12 shares in the last quarter. 98.43% of the stock is currently owned by hedge funds and other institutional investors.
Shares of MEDNAX Inc (MD) opened at $54.22 on Friday. MEDNAX Inc has a 12-month low of $40.56 and a 12-month high of $72.13. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.37 and a current ratio of 1.37. The stock has a market cap of $5,070.00, a P/E ratio of 19.23, a PEG ratio of 1.64 and a beta of 0.39.
MEDNAX (NYSE:MD) last posted its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.87. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The company had revenue of $868.95 million during the quarter, compared to the consensus estimate of $864.78 million. During the same period last year, the firm earned $1.09 EPS. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. sell-side analysts anticipate that MEDNAX Inc will post 3.1 earnings per share for the current year.
In related news, Director Cesar L. Alvarez sold 10,668 shares of MEDNAX stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the transaction, the director now directly owns 44,215 shares in the company, valued at approximately $1,883,116.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Pepia sold 3,000 shares of MEDNAX stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total value of $154,740.00. Following the transaction, the insider now owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by company insiders.
A number of equities research analysts have weighed in on MD shares. KeyCorp raised MEDNAX from a “sector weight” rating to an “overweight” rating and set a $51.00 price objective on the stock in a report on Sunday, September 17th. Piper Jaffray Companies started coverage on MEDNAX in a report on Wednesday, December 13th. They issued an “overweight” rating and a $58.00 price objective on the stock. Jefferies Group reaffirmed a “hold” rating and issued a $44.00 price objective on shares of MEDNAX in a report on Friday, November 3rd. BMO Capital Markets started coverage on MEDNAX in a report on Monday, October 16th. They issued a “market perform” rating and a $46.00 price objective on the stock. Finally, Robert W. Baird lifted their price objective on MEDNAX from $47.00 to $48.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $53.82.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.